Autoimmunity

Feinstein Institutes’ Valentin Pavlov Elected President of the International Society for Autonomic Neuroscience

Retrieved on: 
Wednesday, November 9, 2022
General Health, Other Health, Health, Science, Research, Digestion, Autonomic nervous system, Rheumatoid arthritis, Northwell Health, Pulmonary hypertension, Feinstein Institute for Medical Research, Heart rate, Leadership, Doctor of Philosophy, 3D, ISAN, Vagus nerve, International Society, International Society for Autonomic Neuroscience, Diabetes, Respiration, Communication, Knowledge, Research, NIH, Multimedia, Mental health, Credit, Genetics, Neuron, Brain, Medicine, Injury, Molecular medicine, Biomedical engineering, Inflammation, Cancer, Arthritis, Science, Disorder, Neuroscience, Medical research, Patient, Inflammatory Bowel Diseases, Autoimmunity, Crohn's disease, CEO, Feinstein, Infection, DRS, Blood pressure, Paralysis, Metabolism, Congress, Medical device, Dentistry, Pharmaceutical industry, MD

The International Society for Autonomic Neuroscience (ISAN) has elected The Feinstein Institutes for Medical Research's Valentin Pavlov, PhD , as president in recognition of his dedication and research of the brain and autonomic nervous system, particularly in the regulation of inflammation and metabolism.

Key Points: 
  • The International Society for Autonomic Neuroscience (ISAN) has elected The Feinstein Institutes for Medical Research's Valentin Pavlov, PhD , as president in recognition of his dedication and research of the brain and autonomic nervous system, particularly in the regulation of inflammation and metabolism.
  • View the full release here: https://www.businesswire.com/news/home/20221109005208/en/
    Dr. Valentin Pavlov is a professor at the Feinstein Institutes Institute of Bioelectronic Medicine.
  • It is a privilege and honor to take up the mantle of president for the International Society for Autonomic Neuroscience.
  • Dr. Pavlov's election to president of the International Society for Autonomic Neuroscience is timely evidence of his leadership in bioelectronic medicine, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research.

Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day

Retrieved on: 
Wednesday, November 9, 2022
Health, Stem Cells, Neurology, Research, Science, Pharmaceutical, Biotechnology, T1D, Regulatory T cell, Third Rock Ventures, Lightspeed Venture Partners, Biology, IBM, Multiple sclerosis, Neurology, JDRF, Therapy, Biomarker, Autoimmunity, Type 1 diabetes, Patient, Inflammation, MS, Pharmaceutical industry

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer, and John Trzupek, M.B.A., Ph.D., chief operating officer, will participate in a fireside chat at Guggenheims 4th Annual Immunology and Neurology Day on Monday, November 14, 2022, at 9:00 a.m.

Key Points: 
  • Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer, and John Trzupek, M.B.A., Ph.D., chief operating officer, will participate in a fireside chat at Guggenheims 4th Annual Immunology and Neurology Day on Monday, November 14, 2022, at 9:00 a.m.
  • ET in New York, NY.
  • Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases.
  • Please visit abatatx.com or follow us on Twitter or LinkedIn for more information .

10x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor Discovery

Retrieved on: 
Wednesday, November 9, 2022
Infection, Nature, Software, Assistant, Workflow, Result, Terminology, U.S. Securities and Exchange Commission, Scripps Research, Risk, 10x Genomics, Publication, Conversation, Adoption, SEC, BEAM, Vaccine, Private Securities Litigation Reform Act, Neuroscience, Technology, Disclosure, Regulation, Cancer, Securities Exchange Act of 1934, Financial condition report, Securities Act of 1933, Immune system, Disease, Forward-looking statement, Regulation Fair Disclosure, Genetics, Entrepreneurship, COVID-19, Health, TCR, Genomics, Biology, Social media, Research, Patent, Autoimmunity, Analysis, Therapy, Security (finance)

PLEASANTON, Calif., Nov. 9, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the commercial availability of BEAM (Barcode Enabled Antigen Mapping), a kitted solution for antibody and T-cell receptor (TCR) discovery. Built on top of 10x's industry-leading Chromium Single Cell Immune Profiling product, BEAM's proprietary antigen screening approach is fast and robust, delivering hundreds of antigen-receptor pairs with single cell gene expression. The combination of robust screening; simple, fast, and validated workflows; and, comprehensive interrogation of each cell has the potential to greatly accelerate and improve therapeutic discovery. 

Key Points: 
  • BEAM is the sixth major product launch from 10x Genomics this year, demonstrating the velocity and strength of the company's R&D pipeline.
  • 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health.
  • These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product launches, performance, configuration, capabilities and adoption.
  • These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Retrieved on: 
Tuesday, November 8, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Menopause, Infection, Technology, Euronext Paris, U.S. Securities and Exchange Commission, SEC, Mission statement, Company, Hanover Square, Private Securities Litigation Reform Act, Neuroblastoma, Form 20-F, Central European Time, Prospectus, Degenerative disease, Agency for Science, Technology and Research, MRSA, Autoimmunity, Time, JT Group Limited, Research, Annual report, Therapy, Pharmaceutical industry, EU, Science

Shareholders of record as of October 14, 2022 are entitled to receive notice of and vote at the annual general meeting.

Key Points: 
  • Shareholders of record as of October 14, 2022 are entitled to receive notice of and vote at the annual general meeting.
  • Aptorum Group's annual report on Form 20-F can be accessed in the investor section of Aptorum's website at www.aptorumgroup.com , as well as on the SEC's website at www.sec.gov .
  • Shareholders may request a meeting notice, proxy card or hard copy of the annual report on Form 20-F, free of charge, by contacting [email protected] .
  • This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

Prevent Blindness Declares Third Annual Thyroid Eye Disease (TED) Awareness Week as Nov. 14-20, 2022

Retrieved on: 
Wednesday, November 9, 2022
Cover My Eyes (Pain and Heaven), Horizon Therapeutics, Eye, YouTube, Anxiety, TED, Selenium, Patient, Hyperthyroidism, Swelling, Graves' disease, Graves' ophthalmopathy, Immune system, Risk factor, Program, Awareness, FACS, Inflammation, Severe cognitive impairment, Visual impairment, Art, Depression, Autoimmune disease, Bascom Palmer Eye Institute, Autoimmunity, Social media, Smoking, Research, Quality of life, Risk, Steroid, Emotion, CEO, Pharmaceutical industry, MD, Facebook

CHICAGO, Nov. 9, 2022 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has declared Nov. 14-20, 2022, as its third annual "Thyroid Eye Disease Awareness (TED) Week." TED, sometimes called Graves' ophthalmopathy or Graves' Eye Disease, is an autoimmune disease in which the immune system causes inflammation and swelling and stimulates the production of muscle tissue and fat behind the eye.

Key Points: 
  • Prevent Blindness to provide Thyroid Eye Disease (TED) educational materials, promote awareness, and offer unique Art Therapy program for patients and care partners
    CHICAGO, Nov. 9, 2022 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has declared Nov. 14-20, 2022, as its third annual "Thyroid Eye Disease Awareness (TED) Week."
  • Also available is the "Thyroid Eye Disease" episode of the Focus on Eye Health Expert Series , featuring Prevent Blindness President and CEO Jeff Todd interviewing Sara Wester, MD, FACS, professor of clinical ophthalmology at Bascom Palmer Eye Institute, and TED patient Stephen Bander.
  • TED Awareness Week is supported by Horizon Therapeutics , a global biotechnology company focused on rare, autoimmune and severe inflammatory diseases.
  • Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight.

Cantargia's CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022

Retrieved on: 
Tuesday, November 8, 2022
EU, Skin, Psoriatic arthritis, Fibrosis, Biomarker, ACR, Biotechnology, Clinical trial, Human, Collagen, Disease, Large-cell lung carcinoma, Myocarditis, Inflammation, Pancreatic cancer, Scleroderma, Degenerative disease, IL1RAP, Psoriasis, Nasdaq, Nasdaq Stockholm, Autoimmunity, Research, Peritonitis, CEO, Medical imaging, Pharmaceutical industry, Medical device, Vaccine

LUND, Sweden, Nov. 8, 2022 /PRNewswire/ -- Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported new preclinical data demonstrating positive effects of the IL1RAP-binding antibody CAN10 in three different in vivo models of systemic sclerosis, a lead indication for the drug candidate. Across the models, which mimic difficult-to-treat forms of the disease, CAN10 reduced both pathological inflammation and fibrosis in skin and lung tissue, factors associated with clinical severity in humans. CAN10 also normalized a number of biomarkers closely associated with the human disease. The data have been selected for an oral presentation at ACR Convergence 2022, held in Philadelphia, November 10-14, 2022.

Key Points: 
  • The data have been selected for an oral presentation at ACR Convergence 2022, held in Philadelphia, November 10-14, 2022.
  • "We are pleased to build on previous exciting data on the effects of CAN10 in a number of models of life-threatening diseases.
  • The new results, selected for oral presentation at the prestigious ACR Convergence, demonstrate the potential of CAN10 in systemic sclerosis.
  • The new results show potent activity of a CAN10 surrogate antibody, which reduced inflammation and fibrosis in three different preclinical in vivo models of systemic sclerosis.

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Retrieved on: 
Monday, November 7, 2022
Diagnosis, GLOBE, Pancreas, Liver, Patient, IgG4-related disease, Biotechnology, Shanghai Venture Capital Co., ENAV, Zenas, CD19, Pivotal, GC, Kidney, Toxicity, Autoimmunity, Degenerative disease, Prevalence, Cell, Therapy, Wellington Management Company, End organ damage, Pharmaceutical industry, Security (finance), Management, Series

WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced proceeds of $118 million in connection with the issuance of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor, Inc. also participated in the financing, which included the infusion of new capital as well as the conversion of convertible notes issued to certain of the investors in advance of the closing of the Series B financing.

Key Points: 
  • In addition, the new funding will progress the companys other global autoimmune disease programs into clinical development in 2023.
  • Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world.
  • For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn .
  • Through the application of capital support and operational experience, Enavate strives to enable and empower a diverse portfolio of therapeutics companies to accelerate innovation.

Alpine Immune Sciences to Report Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, ALPN, NASDAQ, Inflammation, Autoimmunity, Protein engineering, Alpine, Webcast, Company, Vaccine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, after the close of market.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, after the close of market.
  • The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NASDAQ, Antibody, Half-life, Atopic dermatitis, Patient, Eosinophil, Biomarker, Cancer, Injection site reaction, CD25, Degenerative disease, Psoriasis, Autoimmune disease, Toxicity, AE, Autoimmunity, Safety, Pharmacokinetics, Cytokine, Vaccine, Regulatory T cell

Tregs combat autoimmunity by suppressing other immune cells from attacking normal tissue; however, in many autoimmune diseases, Tregs become dysregulated.

Key Points: 
  • Tregs combat autoimmunity by suppressing other immune cells from attacking normal tissue; however, in many autoimmune diseases, Tregs become dysregulated.
  • Fusion to our modular XmAb heterodimeric Fc domain with Xtend technology provides a stable protein scaffold and further enhances half-life.
  • In addition, XmAb306 showed accumulation of target immune cells upon repeat dosing, which allows study of further extended dosing intervals and helps inform our development of XmAb564.
  • The study enrolled 48 subjects, with six dose-level cohorts each randomizing six subjects to XmAb564 and two subjects to placebo.

New Digital Tool Dramatically Reduces Blood Clot Risk During and Post-Hospital Care, Feinstein Institutes Study Shows

Retrieved on: 
Monday, November 7, 2022
COVID-19, Research, Hospitals, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Diagnosis, Health information management, American Heart, VTE, Medicine, S-1 Executive Committee, Feinstein Institute for Medical Research, Physician, Thrombosis, Institute, Hospital, Patient, Credit, CDS, Technology, Decision-making, Medical research, Infection, Cancer, EHR, Clinical trial, Executive Committee, ATE, Method, Genetics, Embolism, COVID-19, Late, Stroke, AHA, MIS, Feinstein, Digital technology, Mental health, Science, Northwell Health, Research, Autoimmunity, Multimedia, Risk, Molecular medicine, Health, CEO, Pharmaceutical industry, Medical device, MD

View the full release here: https://www.businesswire.com/news/home/20221107005864/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221107005864/en/
    Dr. Alex Spyropoulos research shows a better way to conduct patient care for those who are suffering from blood clots.
  • (Credit: Feinstein Institutes)
    Dr. Spyropoulos is a world-renowned expert in blood clots who shared critical COVID-19 research during the height of the pandemic.
  • Using the IMPROVE-DD VTE score, doctors can prescribe the appropriate thromboprophylaxis for patients at moderate and high risk of blood clots.
  • The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State.